Coya Therapeutics (COYA) Other Operating Expenses (2022 - 2026)
Coya Therapeutics (COYA) posted Other Operating Expenses of -$1.3 million for Q1 2026, down 531.76% sequentially from $295912.0 in Q4 2025, and up 3.76% YoY from -$1.2 million in Q1 2025.
Coya Therapeutics (COYA) Other Operating Expenses (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Other Operating Expenses for 5 years, with the latest figure at -$1.3 million in Q1 2026.
- Quarterly Other Operating Expenses rose 3.76% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (up 28.1% YoY) and the FY2025 annual result came in at -$3.2 million, up 29.17% from the prior year.
- Other Operating Expenses retreated to -$1.3 million in Q1 2026 per COYA's latest filing, from $295912.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $396840.0 in Q4 2022 and troughed at -$1.5 million in Q2 2025.
- A 5-year average of -$467252.6 and a median of $4033.0 in 2022 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Operating Expenses soared 8748.0% in 2023, then sank 21512.0% in 2024.
- Over 5 years, Other Operating Expenses stood at $396840.0 in 2022, then slumped by 49.6% to $200026.0 in 2023, then plunged by 592.49% to -$985101.0 in 2024, then surged by 130.04% to $295912.0 in 2025, then tumbled by 531.76% to -$1.3 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$1.3 million, $295912.0, and -$659157.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.18 Mn |
| Mar 31, 2026 | -1.28 Mn |
| Dec 31, 2025 | 295,912.00 |
| Sep 30, 2025 | -659,157.00 |
| Jun 30, 2025 | -1.54 Mn |
| Mar 31, 2025 | -1.33 Mn |
| Dec 31, 2024 | -985,101.00 |
| Sep 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -1.04 Mn |
| Mar 31, 2024 | -1.46 Mn |
| Dec 31, 2023 | 200,026.00 |
| Sep 30, 2023 | 6,841.00 |
| Jun 30, 2023 | 356,840.00 |
| Mar 31, 2023 | 6,840.00 |
| Dec 31, 2022 | 396,840.00 |
| Sep 30, 2022 | 147,455.00 |
| Jun 30, 2022 | 4,033.00 |
| Mar 31, 2022 | 4,033.00 |